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Abstract 
 
Introduction: The activity of phosphatases could be influenced by genetic, as well as epigenetic 
alterations. In our study we have investigated the methylation status of four PTPRs: PTPRM, 
PTPRT, PTPRR and PTPRZ1, which were pre-selected using microarray techniques as being 
alternatively methylated in sporadic colorectal cancer.   
Materials and methods: The analyses were carried out on 131 surgical specimens obtained from 
sporadic colorectal cancer patients. The methylation status of the four genes was examined using 
MSP.  
Results:  The analysis of promoter methylation using an Illumina 27K microarray revealed four 
protein tyrosine phosphatases PTPRM, PTPRT, PTPRR and PTPRZ1 as being hypermethylated 
with beta-value ≥ 0.2 and p≤0.05. Subsequent analysis using MSP confirmed these observations - 
the frequency of promoter methylation was significantly higher in tumor cells compared to 
matched normal tissue for each of the analyzed genes. There was no association observed 
between the methylation status of PTPRs and either CIMP, K-ras (codon 12) and BRAF (exon 15, 
V600E) mutations or tumor localization (proximal/distal).  
The results of our study show a statistically significant difference between promoter methylation 
in cancerous and healthy tissue. This result supports the hypothesis that the PTPR family plays an 
important role in the etiology of colorectal cancer. 
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Introduction 
Via dephosphorylation of multiple enzymes, protein tyrosine phosphatases (PTPs) regulate many 
processes, such as cell differentiation and proliferation, apoptosis, gene transcription, mRNA 
processing, molecule transport out of and into cells, as well as cell signaling (1,2). The PTP Cys-
based superfamily is composed of three classes: Class I (classical PTPs) consisting of 
transmembrane receptor PTPs, non-receptor PTPs, as well as dual-specific PTPs, Classes II and 
III consisting of Cdc25 family members and low molecular weight phosphatases respectively (1).  
PTPs play an important role in carcinogenesis acting as tumor suppressor genes (1,2,3).  
Loss of the tumor suppressor function of PTPs, similarly to that of other tumor suppressors, is a 
consequence of gene inactivation resulting from a biallelic inactivation event, such as gene 
deletion, mutation or promoter hypermethylation (4). Methylation of CpG islands located in a 
gene promoter is associated with the downregulation of gene transcription through the alteration 
of chromatin conformation influencing DNA availability to transcription factors (5,6,7).  
Until now, several phosphatases have been examined in human cancers, enabling the assessment 
of their contribution to the development of cancer. Somatic mutations have been found in the 
following six phosphatases: PTPRF, PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14 in 
colorectal cancer. Epigenetic silencing was observed for PTPRR and PTPRG in colorectal cancer 
and cutaneous T-cell lymphoma, for PTPRD in glioblastoma, head and neck squamous cell 
carcinoma and lung cancer, as well as for PTPRO in hepatocellular carcinoma. Moreover, loss of 
heterozygosity was identified for PTPRJ in colorectal cancer (5,8,9,10,11,12).  
The purpose of our study was to analyze the methylation status of colorectal cancer cells. Using a 
genome-wide approach (Illumina Infinium HumanMethylation27), we found 422 differentially 
methylated probes including four members of the tyrosine phosphatase family (PTPRs): PTPRT, 
PTPRR, PTPRM and PTPRZ1.  
These four, but no other protein tyrosine phosphatases, were selected as they were found to be 
alternatively methylated by a microarray experiment .The results were then validated employing 
MSP. The tumor suppressor function of PTPs allowed us to hypothesize that epigenetic silencing 
is a possible mechanism adding to the loss of functioning of these genes in colon cancer cells.  
 
Materials and methods 
Patient samples  
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The study was performed on 131 sporadic colorectal cancer samples compared to matched 
healthy colon tissues. The samples were obtained immediately after surgery from the First 
Department of Surgical Oncology, Lower Silesian Oncology Centre in Wroclaw. The study 
group consisted of 59 females and 72 males with mean age 64.5±10.54 diagnosed with primary 
sporadic colorectal cancer. None of them were treated with preoperative therapy. The molecular 
characteristics of the cancer samples are as follows: the BRAF V600E mutation (exon 15) was 
observed in 8, while the K-ras (codon 12) mutation was found in 31 colon cancer samples. No K-
ras mutation in codon 13 was revealed in our material. CIMP-high and CIMP-low/0 status were 
observed for 7 and 124 tumors, respectively. 
The study was accepted by Wroclaw Medical University Ethical Committee.  
 
Methods 
The samples were obtained during surgery and were frozen at -20oC, until DNA isolation. All 
tissues were examined histopathologically. DNA was isolated from cancer tissue tumor samples 
with at least 40% viable neoplastic cells using a QIAamp DNA mini kit (Qiagen) following the 
recommended protocol. All tissues were examined histopathologically. Methylation status was 
evaluated for 12 pairs of CRC and matched normal colon tissue using Illumina Infinium 
HumanMethylation27. The Benjamini-Hochberg procedure for controlling to the false discovery 
rate was used to correct p-values for multiple testing. All probes with β - values ≥ 0.20 and p ≤ 
0.05 were retained (see supplementary table for the detailed results). Further analysis on an 
additional 131 samples considered four protein tyrosine phosphatase receptor-like genes: PTPRM 
(probeID: cg01946574), PTPRT (probeID: cg13168820), PTPRR (probeID: cg23694248),  and 
PTPRZ1 (probeID: cg25167643), as they showed differential methylation characterized by β - 
values ≥ 0.20 and p ≤ 0.05. The methylation status of these genes was confirmed using MSP 
(Methyl Specific PCR). Primers for methylated and unmethylated promoter sequences were 
designed using MethPrimer software (13) (Table 1).  
 
DNA modification was performed using the EpiTect Bisulfite Kit (Qiagen) according to the 
standard procedure. One μg of DNA isolated from both colorectal cancer and healthy colon tissue 
was modified for each patient. 
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CpG Methylated HELa Genomic DNA (New England Biolabs) and DNA from the peripheral 
blood of a healthy person were used as control DNA for methylated and unmethylated sequences, 
respectively.  
The PCR mixture was prepared separately for methylated and unmethylated sequences for all the 
genes examined. Briefly: 0.6μl modified DNA was mixed with 0.75μl of each primer (10mM) 
0.75μl dNTPs (40mM, Fermentas), 1.5μl buffer (10x, Qiagen), 0.15μl HotStart DNA Polymerase 
(5μ/μl Qiagen) in a total volume of 15 μl.  
The cycle parameters were as follows: 95oC 15min, 95oC 30sec, 56oC 30 sec (methylated and 
unmethylated PTPRM and PTPRZ1) or 60oC (methylated and unmethylated PTPRT, 
unmethylated PTPRR) or 63oC (methylated PTPRR) for 35-38 cycles, 72oC 30 sec and a 72oC 5 




The association between the methylation of PTPRM, PTPRZ1, PTPRT and PTPRR and the type 
of colon cell (cancerous or normal) was analyzed using Fisher’s exact test of association. This 
test was also used to analyze the association of the methylation status of these four PTPRs with 
various clinical factors (e.g. location of cancer, mutations, CIMP status). 
 
Results 
In this study we analyzed the methylation status of four PTPs in 131 sporadic colon cancers (30 
proximal/101 distal) in comparison to matched healthy colon tissues (95 pairs tumor/healthy 
tissue and 36 cancer tissues without paired healthy tissue).  
 
Microarray results: 
Using genome-wide microarray analysis, we found over 400 differentially methylated genes in 
tumor tissues, among which four protein tyrosine phosphatase genes were found as follows: 
PTPRM, PTPRT, PTPRR and PTPRZ1 (see Suppl. Table 1). 
 
MSP results: 
Partial methylation (the presence of both methylated and unmethylated sequences), lack of 
methylation (only unmethylated sequences), as well as complete methylation (only methylated 
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sequences) were observed for the examined phosphatases in cancer tissues (Fig.1). A few 
samples amplified neither of the two sets of primers. The results are presented in Table 3. 
In healthy colon tissues no complete methylation occurred, but cases of partial methylation and 
lack of methylation were common in the following genes: PTPRM, PTPRT and PTPRZ1 with the 
exception of PTPRR, for which complete methylation was found in 2 normal samples (see Table 
3). 
 
Our results revealed a significantly higher level of methylation in tumors compared to normal  
colonnormal colon tissue.  (see Table 4). 
 
There was no significant association of the methylation status of PTPRM, PTPRT, PTPRR or 
PTPRZ1 with CIMP, the K-ras (codon 12) and BRAF (exon 15, V600E) mutations, or tumor 
localization (proximal/distal) (data not shown). 
A clear association between the methylation of PTPRZ1 and PTPRM in healthy cells (p<0.001) 
was also found (Table 5).  
 
Discussion 
An abnormal methylation pattern is a widely described biological phenomenon in cancer cells. 
Global hypomethylation, promoting genomic instability and regional hypermethylation of CpG 
islands at gene promoters associated with transcriptional silencing of the tumor suppressor gene, 
has been reported in many types of cancers (6). In particular, the hypermethylation of tumor 
suppressor gene promoters leading to loss of their function is an important event in the molecular 
pathogenesis of cancer (14).   
Our results revealed that the promoter sequences of four protein tyrosine phosphatases: PTPRM, 
PTPRT, PTPRR and PTPRZ1, are hypermethylated in colon cancer compared to healthy colon 
tissue. These data were obtained using a methylation microarray and then confirmed by 
methylation-specific PCR. Methylated and unmethylated sequences were both often observed in 
healthy colon tissues in our study, although the frequency of methylated sequences was 
significantly lower than in cancer tissues (for PTPRM, PTPRT, PTPRZ1 p=0 and for PTPRR 
p=0.028350.01988). However, using MSP only the presence of a methylated allele in the tissue 
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examined could be shown without the possibility of distinguishing between uni- and biallelic 
methylation.  
These observations should be analyzed  in the context of the possibility ofa possible role of  PTPs 
playing a role in the development of cancer transformation. As it has been published recently, In 
several previous studies the biological role of selected thean involvement of PTPs in 
cancerogenesis has been observed for  a variety of tumors.  PTPRT (PTPR-rho) is a known tumor 
suppressor, mutations of which are associated with melanoma, colon, stomach and lung cancer 
(3). As reported previously, PTPRT mutations may cause loss of its function (nonsense or 
frameshift mutations), a decrease in phosphatase activity or defective cell adhesion (missense 
mutations in phosphatase and extracellular domains, respectively) (3,8). Moreover, an increase in 
PTPRT activity in a tumor cell culture inhibited cell growth (8). 
PTPRZ1 (PTPR-zeta or PTPR-beta) is a receptor of VacA, a cytotoxin of Helicobacter pylori, 
inducing gastric ulcers (15). PTPRZ1 has also been reported to play an important role in the 
functioning of neurons (15). There are no reports on its role as a tumor suppressor or its 
significance for cell homeostasis. 
PTPRM (PTPR-mu) is a member of the Ig superfamily of adhesion molecules and has been 
shown to be expressed in neurons, glia, epithelia and prostate (16,17,18). PTPRM plays a crucial 
role in EGFR signaling – reduced expression of PTPRM increases the EGFR specific 
phosphorylation of tyrosine residue, thus causing phospholipase C-gamma (PLC)γ1 activation 
and  cell migration (18). It is also known that EGFR activation via phosphorylation can itself 
increase cell proliferation, differentiation and survival (18). The increased expression of PTPRM 
in normal cell and low-grade astrocytomas compared to high grade glioblastomas, along with the 
results of in vivo experiments, also confirmed that loss of this protein promotes tumor cell 
migration and propagation (17). The lack of expression of PTPRM in prostate cancer cells 
connected with the lack of PTPRM-mediated adhesion also suggests a role of PTPRM as a tumor 
suppressor gene (16).  
PTPRR was firstly described by Menigatti et al. 2009 to be highly downregulated in the early 
stages of colorectal tumorigenesis. This gene encoding a classical PTP receptor plays a crucial 
role in homeostasis regulating signaling in proliferation and differentiation (9). 
PTPRT was the only gene for which there was no methylated sequence observed in the control 
samples. The importance of PTPRT in colon cancer has been postulated by Wang et al. (2004) 
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(8). Our results support this hypothesis, showing that the most probable role of PTPRT is the 
suppression of carcinogenesis. However, further studies are needed to confirm this hypothesis. 
We also found a clear association between the methylation of PTPRZ1 and PTPRM in healthy 
cells (p<0.001). Up to now, no data suggesting any biological interaction between these genes 
has been published.  PTPRM is known to play a crucial role in the EGFR signaling pathway and 
thus in cell migration, while the role of PTPRZ1 is still poorly described. Up to now, the 
expression of PTPRZ1 has only been shown in neurons. Our results are the first revealing a 
potential role of this gene in colon cells. 
EarlierRecent epigenomic microarray analyses of aberrantly methylated genes in CRC tissues 
have identified many hypermethylated gene promoters which were hypermethylated . Thus it has 
been postulated that these genesthat can may influencinfluencebe involvede in colorectal 
tumorigenesis. In the studiesy of Kim et al. (2011) and Hinoue et al. (2012) the Illumina platform 
has been used tofor analyzesis of 22 and 125 tumor samples respectively (19,20). 
AlthoughtAlthough these autorsauthors have not mentioned about PTPs in theirtop  “top ranking 
lists” of genes with aberrant methylation, the available raw data shows differences in PTPs 
methylation accordingas compared to healthy tissue (19,20). 
Our study, which seems to be the first analysis using MSP of the methylation status of PTPRS 
PTPRs in sporadic colon cancer, has enabled us to conclude that the methylation of PTPRs is 
significantly different in cancerous and healthy tissue. This suggests a potential role of these 
genes as suppressors in colorectal carcinogenesis. Moreover, our results revealing alterations in 
PTPRZ1 methylation in normal colon samples led us to hypothesize that this gene plays a still 
unknown role in the colon. 
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